|Hyderabad, India, March 05, 2014|
Dr. Reddy’s announces the Launch of Moxifloxacin Hydrochloride Tablets
Hyderabad, India, March 05, 2014
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) announced today that it has launched Moxifloxacin Hydrochloride Tablets, 400 mg, a therapeutic equivalent generic version of Avelox® (moxifloxacin HCl) tablets 400 mg in the US market on March 04, 2014, following the approval by the United States Food & Drug Administration (USFDA).
The Avelox® (moxifloxacin HCl) tablets brand had U.S. sales of approximately $195 Million for the most recent twelve months ending in December 2013 according to IMS Health*.
Dr. Reddy’s Moxifloxacin Hydrochloride Tablets, 400 mg is available in bottle counts of 30.
Avelox® is a registered trademark of Bayer Aktiengesellschaft and is used under license by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
*IMS National Sales Perspectives: Retail and Non-Retail December 2013.
For more information please contact:
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Major therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infective. Major markets include India, USA, Russia-CIS and Europe apart from other select geographies within Emerging Markets. For more information, log on to:www.drreddys.com